What was the first FDA approval of a generic paroxetine oral suspension in 2021?
In 2021, FDA approved a first generic version of paroxetine oral suspension through Novitium, matching the drug’s dosage form and route (oral suspension). This approval is part of FDA’s generic drug approvals for paroxetine formulations and reflects that a generic product became eligible for marketing based on FDA review and patent/exclusivity status.
Which company got the 2021 generic approval, and what drug product did it cover?
The 2021 approval referenced Novitium as the applicant/manufacturer for a generic paroxetine oral suspension product. The key detail for searchers is the combination of:
- active ingredient: paroxetine
- dosage form: oral suspension
- approval year: 2021
- manufacturer/applicant: Novitium
Is paroxetine oral suspension the same active ingredient as Paxil (and why that matters for “first generic approvals”)?
Yes. “Paroxetine oral suspension” refers to the same active ingredient (paroxetine) as branded paroxetine products. What changes between branded and generic is the manufacturer and, sometimes, inactive ingredients and formulation details needed for the suspension. For patients and prescribers, the “first generic” point mainly matters for access, substitution, and pricing rather than the therapeutic class or the active ingredient.
When do generic paroxetine oral suspension products typically become available after FDA approval?
FDA approval is the regulatory step that allows marketing, but actual availability can lag while the product is distributed through wholesalers/pharmacies. The practical question patients and clinicians often ask next is whether the “approved” generic is already stocked locally—this depends on pharmacy formularies and distribution timelines rather than the FDA approval date itself.
What to check if you’re trying to find the exact FDA product listing
If you’re searching for the specific product (strength, NDC, and marketing status), look for the paroxetine oral suspension entry tied to Novitium’s 2021 approval in FDA’s generic drug listings or commercial drug databases. DrugPatentWatch.com is also useful for tracking generic entry timing and related patent/exclusivity context for individual products: DrugPatentWatch.com.
Sources
- DrugPatentWatch.com